ATCC has been awarded an Indefinite Delivery/Indefinite Quantity (IDIQ) contract (number 75N93025D00017) with an ordering period of 7 years with Federal funds from the National Institute of Allergy and Infectious Diseases (NIAID), an institute within the National Institutes of Health (NIH) and the Department of Health and Human Services (HHS). The contract, with an initial award of $10,000, potentially valued up to $136.6 million, supports NIAID’s Evaluation and Testing Services (ETS) program for vaccines and other biologics used to fight infectious diseases.
Under this award, ATCC will apply its scientific expertise to deliver comprehensive assay development and test preclinical and clinical samples—work that helps accelerate the development of vaccines, biologics, and other medical countermeasures for emerging and re-emerging infectious diseases.
“This award reflects the responsibility we share in safeguarding public health,” said ATCC Federal Solutions Senior Vice President Rebecca Bradford, MBA, MS, PMP. “Building on our long partnership with NIAID, we’re proud to support work that strengthens U.S. preparedness and helps protect communities. Our teams understand the impact behind every sample and every data point, and we’re honored to contribute to the nation’s response to emerging public health threats.”
ATCC is well-positioned to support this contract, backed by decades of experience in managing NIAID’s Biological and Emerging Infections Program, which provides reagents, tools, and information for studying pathogens, emerging infectious disease agents, non-pathogenic microbes, and other microbiological materials of relevance to the research community. ATCC has also played a key role in global responses to major outbreaks, including COVID 19, H1N1, Ebola, and Zika, by rapidly supplying authenticated biological materials and standards.
“Through this contract, ATCC continues to support NIAID’s research efforts by delivering the biological standards, materials, and expertise needed to study emerging infectious diseases,” Bradford added. “We’re proud to expand our partnership with NIAID and to provide the resources, processes, and technology that help protect public health.”
This work reflects ATCC’s ongoing commitment to protect public health through scientific rigor and proven expertise.
Read more here.